CR20230436A - Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos - Google Patents
Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usosInfo
- Publication number
- CR20230436A CR20230436A CR20230436A CR20230436A CR20230436A CR 20230436 A CR20230436 A CR 20230436A CR 20230436 A CR20230436 A CR 20230436A CR 20230436 A CR20230436 A CR 20230436A CR 20230436 A CR20230436 A CR 20230436A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tl1a
- compositions
- tnf
- ligand
- humanized antibodies
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento, se describen anticuerpos humanizados anti-TL1A y composiciones farmacéuticas para el tratamiento de enfermedades inflamatorias intestinales (IBD), tales como la enfermedad de Crohn (CD) y colitis ulcerosa (UC).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163150825P | 2021-02-18 | 2021-02-18 | |
US202163180892P | 2021-04-28 | 2021-04-28 | |
US202163226037P | 2021-07-27 | 2021-07-27 | |
US202163285781P | 2021-12-03 | 2021-12-03 | |
PCT/US2022/016841 WO2022178159A1 (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230436A true CR20230436A (es) | 2023-11-01 |
Family
ID=82931032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230436A CR20230436A (es) | 2021-02-18 | 2022-02-17 | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4294444A1 (es) |
JP (1) | JP2024506940A (es) |
KR (1) | KR20230157973A (es) |
AU (1) | AU2022223420A1 (es) |
BR (1) | BR112023016672A2 (es) |
CA (1) | CA3207817A1 (es) |
CL (1) | CL2023002424A1 (es) |
CO (1) | CO2023011969A2 (es) |
CR (1) | CR20230436A (es) |
DO (1) | DOP2023000162A (es) |
EC (1) | ECSP23070237A (es) |
IL (1) | IL305312A (es) |
MX (1) | MX2023009622A (es) |
PE (1) | PE20231681A1 (es) |
TW (1) | TW202246322A (es) |
WO (1) | WO2022178159A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
JP6740126B2 (ja) * | 2013-11-13 | 2020-08-12 | ファイザー・インコーポレイテッド | 腫瘍壊死因子様リガンド1a特異的抗体ならびにその組成物および使用 |
JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ,インク. | 最適化された抗tl1a抗体 |
-
2022
- 2022-02-17 IL IL305312A patent/IL305312A/en unknown
- 2022-02-17 PE PE2023002389A patent/PE20231681A1/es unknown
- 2022-02-17 KR KR1020237031689A patent/KR20230157973A/ko unknown
- 2022-02-17 CR CR20230436A patent/CR20230436A/es unknown
- 2022-02-17 MX MX2023009622A patent/MX2023009622A/es unknown
- 2022-02-17 CA CA3207817A patent/CA3207817A1/en active Pending
- 2022-02-17 BR BR112023016672A patent/BR112023016672A2/pt unknown
- 2022-02-17 AU AU2022223420A patent/AU2022223420A1/en active Pending
- 2022-02-17 TW TW111105898A patent/TW202246322A/zh unknown
- 2022-02-17 WO PCT/US2022/016841 patent/WO2022178159A1/en active Application Filing
- 2022-02-17 EP EP22756949.8A patent/EP4294444A1/en active Pending
- 2022-02-17 JP JP2023549820A patent/JP2024506940A/ja active Pending
-
2023
- 2023-08-16 CL CL2023002424A patent/CL2023002424A1/es unknown
- 2023-08-17 DO DO2023000162A patent/DOP2023000162A/es unknown
- 2023-09-08 CO CONC2023/0011969A patent/CO2023011969A2/es unknown
- 2023-09-14 EC ECSENADI202370237A patent/ECSP23070237A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202246322A (zh) | 2022-12-01 |
CO2023011969A2 (es) | 2023-09-29 |
KR20230157973A (ko) | 2023-11-17 |
IL305312A (en) | 2023-10-01 |
ECSP23070237A (es) | 2023-10-31 |
EP4294444A1 (en) | 2023-12-27 |
PE20231681A1 (es) | 2023-10-19 |
DOP2023000162A (es) | 2023-10-15 |
WO2022178159A1 (en) | 2022-08-25 |
AU2022223420A1 (en) | 2023-09-21 |
CA3207817A1 (en) | 2022-08-25 |
CL2023002424A1 (es) | 2024-01-05 |
BR112023016672A2 (pt) | 2023-11-21 |
MX2023009622A (es) | 2023-08-28 |
JP2024506940A (ja) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001016A1 (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos | |
HRP20201600T1 (hr) | Anti-pd-1 antitijelo i njegova uporaba | |
ECSP23070234A (es) | Anti-cd30l antibodies and uses thereof | |
MY191324A (en) | Neutralizing anti-tl1a monoclonal antibodies | |
CO2022006679A2 (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos | |
UY33715A (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a) | |
BR112014021251A2 (pt) | anticorpos humanos para toxinas de clostridium difficile | |
EA201790088A1 (ru) | Ингибиторы syk | |
WO2019209995A3 (en) | Optimized anti-tl1a antibodies | |
JP2017518258A5 (es) | ||
EA201390874A1 (ru) | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение | |
HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
CL2021000033A1 (es) | Nuevos compuestos | |
MX2019012051A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
EP4268820A3 (en) | Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease | |
BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
ECSP23070237A (es) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
BR112022019958A2 (pt) | Composições e métodos para o tratamento de doenças inflamatórias do intestino utilizando anticorpos inibidores de ccr9 e anticorpos de bloqueio anti-il -23 | |
DOP2023000160A (es) | Anticuerpos anti-cd30l y usos de estos | |
EA202191393A1 (ru) | Стабильная вакцина против clostridium difficile | |
BR112020026507A8 (pt) | Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4 | |
RU2013155270A (ru) | Инденовые производные для применения в лечении воспалительного заболевания кишечника | |
EA202190578A1 (ru) | ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2 | |
EA202191738A1 (ru) | Соединения имидазопиридазина и имидазопиридина и их применение | |
EA202191724A1 (ru) | Ингибиторы пути jak1 для лечения заболевания желудочно-кишечного тракта |